Logotipo del repositorio
Logotipo del repositorio
 

Las dislipidemias y su tratamiento en centros de altacomplejidad en Colombia

Vista sencilla de ítem
dc.contributor.authorRuiz, Álvaro J.
dc.contributor.authorVargas-Uricoechea, Hernando
dc.contributor.authorUrina-Triana, Miguel
dc.contributor.authorRomán-González, Alejandro
dc.contributor.authorIsazae, Daniel
dc.contributor.authorEtayof, Edwin
dc.contributor.authorQuintero, Adalberto
dc.contributor.authorMolina, Dora Inés
dc.contributor.authorToro, Juan Manuel
dc.contributor.authorParra, Gustavo
dc.contributor.authorMerchán, Alonso
dc.contributor.authorCadena, Alberto
dc.contributor.authorYupanqui Lozano, Hernán
dc.contributor.authorCárdenas, Juan Mauricio
dc.contributor.authorQuintero, Álvaro Mauricio
dc.contributor.authorBotero, Rodrigo
dc.contributor.authorJaramillo, Mónica
dc.contributor.authorArteaga, Juan Manuel
dc.contributor.authorVesga-Angaritar, Boris
dc.contributor.authorValenzuela-Plata, Etna
dc.contributor.authorBetancur-Valencia, Mónica
dc.date.accessioned2020-05-23T19:37:26Z
dc.date.available2020-05-23T19:37:26Z
dc.date.issued2020
dc.description.abstractAntecedentes y objetivo: Los datos sobre la distribución de las dislipidemias en Colombia sonlimitados. El objetivo primario de este estudio fue describir la frecuencia de las dislipidemias; los objetivos secundarios fueron: la frecuencia de comorbilidades cardiovasculares, el uso de estatinas y otros hipolipemiantes, la frecuencia de intolerancia a estatinas, el porcentaje de pacientes en metas de c-LDL, y estimar la distribución del riesgo cardiovascular (RCV).Materiales y métodos: Estudio transversal con recolección de datos retrospectiva que incluyóa 461 pacientes con diagnóstico de dislipidemia tratados en 17 centros cardiovasculares de altacomplejidad en las 6 principales áreas geográficas y económicas de Colombia.Resultados: La media (DE) de edad de los pacientes incluidos fue de 66,4 (±12,3) a˜nos. El 53,4%(246) eran mujeres. Las dislipidemias se distribuyeron así: dislipidemia mixta (51,4%), hiperco-lesterolemia (41,0%), hipertrigliceridemia (5,4%), hipercolesterolemia familiar (3,3%) y c-HDLbajo (0,7%). El medicamento más prescrito fue atorvastatina (75,7%), seguido de rosuvastatina(24,9%). El 55% del total de pacientes y el 28,6% de aquellos con enfermedad coronaria noestaban en metas de c-LDL a pesar del tratamiento. La frecuencia de intolerancia a estatinas fue del 2,6%.Conclusiones: La dislipidemia mixta y la hipercolesterolemia son las dislipidemias más frecuentes. Un porcentaje considerable de pacientes en tratamiento, incluidos aquellos con enfermedad coronaria, no lograron sus objetivos de c-LDL. Este inadecuado control lipídicoinfluye en el RCV y requiere un cambio en las estrategias terapéuticas, intensificando el trata-miento con estatinas o adicionando nuevos fármacos en los pacientes con mayor RCV.© 2020 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.spa
dc.description.abstractBackground and objective: Data is scarce on the distribution of different types of dyslipidae-mia in Colombia. The primary objective was to describe the frequency of dyslipidaemias. Thesecondary objectives were: frequency of cardiovascular comorbidity, statins and other lipid-lowering drugs use, frequency of statins intolerance, percentage of patients achieving c-LDLgoals, and distribution of cardiovascular risk (CVR).Materials and methods: Cross-sectional study with retrospective data collection from 461patients diagnosed with dyslipidaemia and treated in 17 highly specialised centres distributedinto six geographic and economic regions of Colombia.Results: Mean (SD) age was 66.4 (±12.3) years and 53.4% (246) were women. Dyslipidaemiaswere distributed as follows in order of frequency: mixed dyslipidaemia (51.4%), hypercholes-terolaemia (41.0%), hypertriglyceridaemia (5.4%), familial hypercholesterolaemia (3.3%), andlow c-HDL (0.7%). The most prescribed drugs were atorvastatin (75.7%) followed by rosuvas-tatin (24.9%). As for lipid control, 55% of all patients, and 28.6% of those with coronary heartdisease, did not achieve their personal c-LDL goal despite treatment. The frequency of statinintolerance was 2.6% in this study.Conclusions: Mixed dyslipidaemia and hypercholesterolaemia are the most frequent dyslipidae-mias in Colombia. A notable percentage of patients under treatment with lipid-lowering drugs,including those with coronary heart disease, did not achieve specific c-LDL goals. This poor lipidcontrol may worsen patient’s CVR, so that therapeutic strategies need to be changed, eitherwith statin intensification or addition of new drugs in patients with higher CVR.© 2020 Sociedad Espa˜nola de Arteriosclerosis. Published by Elsevier Espa˜na, S.L.U. All rightsreserved.eng
dc.format.mimetypepdfspa
dc.identifier.doihttps://doi.org/10.1016/j.arteri.2019.11.005
dc.identifier.issn15781879
dc.identifier.urihttps://hdl.handle.net/20.500.12442/5732
dc.identifier.urlhttps://www.sciencedirect.com/science/article/abs/pii/S0214916820300036?via%3Dihub
dc.language.isospaspa
dc.publisherSociedad Espanola de Arteriosclerosisspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceClínica e investigación en Arteriosclerosisspa
dc.sourceVol. 3, (2020)
dc.subjectAterosclerosisspa
dc.subjectEnfermedad cardiovascularspa
dc.subjectDislipidemiaspa
dc.subjectEstatinasspa
dc.subjectHipercolesterolemia familiarspa
dc.subjectAtherosclerosiseng
dc.subjectCardiovascular diseaseeng
dc.subjectDyslipidaemiaeng
dc.subjectStatinseng
dc.subjectFamilial hypercholesterolaemiaeng
dc.titleLas dislipidemias y su tratamiento en centros de altacomplejidad en Colombiaspa
dc.typearticleeng
dc.type.driverarticleeng
dcterms.referencesLaslett LJ, Alagona P, Clark BA, Drozda JP, Saldivar F, Wilson SR,et al. The worldwide environment of cardiovascular disease:prevalence, diagnosis, therapy, and policy issues: a report fromthe American College of Cardiology. J Am Coll Cardiol. 2012;60Suppl.:S1---49, http://dx.doi.org/10.1016/j.jacc.2012.11.002.eng
dcterms.referencesTownsend N, Nichols M, Scarborough P, Rayner M. Car-diovascular disease in Europe–epidemiological update2015. Eur Heart J. 2015;36:2696---705, http://dx.doi.org/10.1093/eurheartj/ehv428.eng
dcterms.referencesMozaffarian D, Benjamin EJ, Go AS, Arnett DK, BlahaMJ, et al., American Heart Association Statistics Com-mittee and Stroke Statistics Subcommittee. Heart diseaseand stroke statistics-2016 update: a report from theAmerican Heart Association. Circulation. 2016;133:e38---60,http://dx.doi.org/10.1161/CIR.0000000000000350.eng
dcterms.referencesPAHO/WHO. Health in South America. Health SituationPolicies and Systems Overview; 2012 [consultado 1 Sep2018]. Disponible en: http://new.paho.org/chi/images/PDFs/health%20in%20sam%202012%20(jan.13).pdf.eng
dcterms.referencesWHO. Non-communicable diseases country profiles. 2014[consultado 1 Sep 2018]. Disponible en: http://apps.who.int/iris/bitstream/handle/10665/128038/9789241507509 eng.pdf;jsessionid=8E61B7F0E4DA183C5125036DAEF5F05C?sequence=1eng
dcterms.referencesWHO. Cardiovascular disease: Global Atlas on Cardiovas-cular Disease Prevention and Control. 2012 [consultado1 Sep 2018]. Disponible en: http://www.who.int/cardiovascular diseases/publications/atlas cvd/en/eng
dcterms.referencesSmith SC, Collins A, Ferrari R, Holmes DR, LogstrupS, McGhie DV, et al. Our time: a call to save pre-ventable death from cardiovascular disease (heartdisease and stroke). J Am Coll Cardiol. 2012;60:2343---8,http://dx.doi.org/10.1016/j.jacc.2012.08.962.eng
dcterms.referencesFalk E. Pathogenesis of atherosclerosis. J Am CollCardiol. 2006;47 Suppl.:C7---12, http://dx.doi.org/10.1016/j.jacc.2005.09.068.eng
dcterms.referencesChan DC, Barrett PHR, Watts GF. The metabolic andpharmacologic bases for treating atherogenic dyslipidae-mia. Best Pract Res Clin Endocrinol Metab. 2014;28:369---85,http://dx.doi.org/10.1016/j.beem.2013.10.001.eng
dcterms.referencesMusunuru K. Atherogenic dyslipidemia: cardiovascularrisk and dietary intervention. Lipids. 2010;45:907---14,http://dx.doi.org/10.1007/s11745-010-3408-1.eng
dcterms.referencesAustin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipo-protein phenotype. A proposed genetic marker for coronaryheart disease risk. Circulation. 1990;82:495---506.eng
dcterms.referencesTaylor F, Huffman MD, Macedo AF, Moore THM, Burke M, DaveySmith G, et al. Statins for the primary prevention of cardio-vascular disease. Cochrane Database Syst Rev. 2013:CD004816,http://dx.doi.org/10.1002/14651858.CD004816.pub5.eng
dcterms.referencesGoff DC, Lloyd-Jones DM, Bennett G, Coady S, D’AgostinoRB, Gibbons R, et al. 2013 ACC/AHA guideline on theassessment of cardiovascular risk: a report of the AmericanCollege of Cardiology/American Heart Association Task Forceon Practice Guidelines. J Am Coll Cardiol. 2014;63:2935---59,http://dx.doi.org/10.1016/j.jacc.2013.11.005.eng
dcterms.referencesCatapano AL, Graham I, de Backer G, Wiklund O, Chap-man MJ, Drexel H, et al., The Task Force for themanagement of dyslipidaemias of the European Societyof Cardiology (ESC) and European Atherosclerosis Society(EAS) developed with the special contribution of theEuropean Association for Cardiovascular Prevention & Reha-bilitation (EACPR). 2016 ESC/EAS Guidelines for the mana-gement of dyslipidaemias. Atherosclerosis. 2016;253:281---344,http://dx.doi.org/10.1016/j.atherosclerosis.2016.08.018.eng
dcterms.referencesMancini GBJ, Baker S, Bergeron J, Fitchett D, Froh-lich J, Genest J, et al. Diagnosis, prevention, andmanagement of statin adverse effects and intole-rance: proceedings of a Canadian Working GroupConsensus Conference. Can J Cardiol. 2011;27:635---62,http://dx.doi.org/10.1016/j.cjca.2011.05.007.eng
dcterms.referencesPijlman AH, Huijgen R, Verhagen SN, Imholz BPM,Liem AH, Kastelein JJP, et al. Evaluation of choles-terol lowering treatment of patients with familialhypercholesterolemia: a large cross-sectional studyin The Netherlands. Atherosclerosis. 2010;209:189---94,http://dx.doi.org/10.1016/j.atherosclerosis.2009.09.014.eng
dcterms.referencesMinisterio de Salud de Colombia. Encuesta Nacional deSalud. 2007 [consultado 1 Sep 2018]. Disponible en: https://www.minsalud.gov.co/Documentos%20y%20Publicaciones/ENCUESTA%20NACIONAL.pdfspa
dcterms.referencesObservatorio Nacional de Salud. Enfermedad cardiovascular:principal causa de muerte en Colombia. 2013 [consul-tado 1 Sep 2018]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/INS/Boletin-tecnico-1-ONS.pdfspa
dcterms.referencesHernández-Hernández R, Silva H, Velasco M, Pellegrini F, Mac-chia A, Escobedo J, et al. Hypertension in seven Latin Americancities: the Cardiovascular Risk Factor Multiple Evaluation inLatin America (CARMELA) study. J Hypertens. 2010;28:24---34,http://dx.doi.org/10.1097/HJH.0b013e328332c353.eng
dcterms.referencesNational Cholesterol Education Program (NCEP) Expert Panel onDetection, Evaluation, and Treatment of High Blood Choleste-rol in Adults (Adult Treatment Panel III). Third Report of theNational Cholesterol Education Program (NCEP) Expert Panel onDetection Evaluation, and Treatment of High Blood Cholesterolin Adults (Adult Treatment Panel III) final report. Circulation.2002;106:3143---421.eng
dcterms.referencesMachado-Alba JE, Machado-Duque ME. [Cardiovascular risk fac-tors prevalence among patients with dyslipidemia in Colombia].Rev Peru Med Exp Salud Publica. 2013;30:205---11.eng
dcterms.referencesGonzález-Rivas JP, Nieto-Martínez R, Brajkovich I, Ugel E,Rísquez A. Prevalence of dyslipidemias in three regions inVenezuela: The VEMSOLS study results. Arq Bras Cardiol.2018;110:30---5, http://dx.doi.org/10.5935/abc.20170180.eng
dcterms.referencesGuallar-Castillón P, Gil-Montero M, León-Mu˜noz LM,Graciani A, Bayán-Bravo A, Taboada JM, et al. Mag-nitude and management of hypercholesterolemia inthe adult population of Spain, 2008-2010: The ENRICAstudy. Rev Esp Cardiol (Engl Ed). 2012;65:551---8,http://dx.doi.org/10.1016/j.recesp.2012.02.005.eng
dcterms.referencesDe la Sierra A, Pintó X, Guijarro C, Miranda JL, Callejo D, CuervoJ, et al. Prevalence, treatment, and control of hypercholestero-lemia in high cardiovascular risk patients: evidences from a sys-tematic literature review in Spain. Adv Ther. 2015;32:944---61,http://dx.doi.org/10.1007/s12325-015-0252-y.eng
dcterms.referencesToro JM, Román-González A, Builes-Barrera CA. Iden-tifying familial hypercholesterolemia in Colombia. JClin Lipidol. 2017;11:1106---7, http://dx.doi.org/10.1016/j.jacl.2017.05.008.eng
dcterms.referencesMerchán A, Ruiz ÁJ, Campo R, Prada CE, Toro JM,Sánchez R, et al. Hipercolesterolemia familiar: artículode revisión. Rev Colomb Cardiol. 2016;23 Supl. 4:4---26,http://dx.doi.org/10.1016/j.rccar.2016.05.002.eng
dcterms.referencesCannon CP, Blazing MA, Giugliano RP, McCagg A, White JA,Theroux P, et al. Ezetimibe added to statin therapy afteracute coronary syndromes. N Engl J Med. 2015;372:2387---97,http://dx.doi.org/10.1056/NEJMoa1410489.eng
dcterms.referencesSabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD,Murphy SA, et al. Evolocumab and clinical outcomes in patientswith cardiovascular disease. N Engl J Med. 2017;376:1713---22,http://dx.doi.org/10.1056/NEJMoa1615664.eng
dcterms.referencesSchwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA,Diaz R, et al. Alirocumab and cardiovascular outcomes afteracute coronary syndrome. N Engl J Med. 2018;379:2097---107,http://dx.doi.org/10.1056/NEJMoa1801174.eng
dcterms.referencesJellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT,Fonseca VA, Garber AJ, et al. American Association of Cli-nical Endocrinologists and American College of Endocrinologyguidelines for management of dyslipidemia and preventionof cardiovascular disease - Executive summary. Endocr Pract.2017;23:479---97, http://dx.doi.org/10.4158/EP171764.GL.eng
dcterms.referencesStone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN,Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline onthe treatment of blood cholesterol to reduce atherosclero-tic cardiovascular risk in adults: a report of the AmericanCollege of Cardiology/American Heart Association Task Forceon Practice Guidelines. J Am Coll Cardiol. 2014;63:2889---934,http://dx.doi.org/10.1016/j.jacc.2013.11.002.eng
dcterms.referencesStroes ES, Thompson PD, Corsini A, Vladutiu GD, RaalFJ, Ray KK, et al. Statin-associated muscle symp-toms: impact on statin therapy-European AtherosclerosisSociety Consensus Panel Statement on Assessment Aetio-logy and Management. Eur Heart J. 2015;36:1012---22,http://dx.doi.org/10.1093/eurheartj/ehv043.eng
dcterms.referencesDanchin N, Almahmeed W, Al-Rasadi K, Azuri J, BerrahA, Cuneo CA, et al. Achievement of low-density lipo-protein cholesterol goals in 18 countries outside WesternEurope: The International ChoLesterol management Prac-tice Study (ICLPS). Eur J Prev Cardiol. 2018;25:1087---94,http://dx.doi.org/10.1177/2047487318777079.eng
dcterms.referencesCamacho P, Otero J, Pérez M, Arcos E, García H, NarvaezC, et al. The spectrum of the dyslipidemia in Colom-bia: The PURE study. Int J Cardiol. 2019;284:111---133678,http://dx.doi.org/10.1016/j.ijcard.2018.10.090.eng
dcterms.referencesGonzález MA, Dennis RJ, Devia JH, Echeverri D, Brice˜no GD, GilF, et al. [Risk factors for cardiovascular and chronic diseasesin a coffee-growing population]. Rev Salud Publica (Bogotá).2012;14:390---403.eng
dcterms.referencesPati˜no-Villada FA, Arango-Vélez EF, Quintero-Velásquez MA,Arenas-Sosa MM. [Cardiovascular risk factors in an urban Colom-bia population]. Rev Salud Publica (Bogotá). 2011;13:433---45.eng
dcterms.referencesVinueza R, Boissonnet CP, Acevedo M, Uriza F, Beni-tez FJ, Silva H, et al., CARMELA Study Investigators.Dyslipidemia in seven Latin American cities: CARMELAstudy. Prev Med. 2010;50:106---11, http://dx.doi.org/10.1016/j.ypmed.2009.12.011.eng
dcterms.referencesBautista LE, Oróstegui M, Vera LM, Prada GE, Orozco LC,Herrán OF. Prevalence and impact of cardiovascular risk fac-tors in Bucaramanga Colombia: results from the CountrywideIntegrated Noncommunicable Disease Intervention Programme(CINDI/CARMEN) baseline survey. Eur J Cardiovasc Prev Rehabil.2006;13:769---75.eng
dcterms.referencesPonte-Negretti CI, Isea-Perez JE, Lorenzatti AJ, Lopez-Jaramillo P, Wyss QFS, Pintó X, et al. Atherogenic dyslipi-demia in Latin America: Prevalence, causes and treatment:Expert’s position paper made by The Latin American Aca-demy for the Study of Lipids (ALALIP) Endorsed by theInter-American Society of Cardiology (IASC), the SouthAmerican Society of Cardiology (SSC), the Pan-AmericanCollege of Endothelium (PACE), and the International Athe-rosclerosis Society (IAS). Int J Cardiol. 2017;243:516---22,http://dx.doi.org/10.1016/j.ijcard.2017.05.059.eng
oaire.versioninfo:eu-repo/semantics/publishedVersionspa

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca